Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURE-01: Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
NCT02736266Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Feb 2017
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in urothelial bladder carcinoma (UBC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathologic Complete Response at 9 weeks. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
urothelial bladder carcinoma (UBC)
Beyond the preview
Go deeper on NCT02736266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736266.